Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is a promising company in the medical technology industry, with its AI-enabled personalized platform positioned to revolutionize spine surgery. Key factors driving this positive outlook include strong third-party reimbursement, efficient production and delivery processes, and the company's expansion into the cervical spine market. Despite risks such as competition and reimbursement changes, Carlsmed's high growth and attractive hospital economics make it a compelling investment opportunity.

Bears say

Carlsmed is a single-segment, commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. Despite recent revenue upside and increased utilization, the company still faces potential challenges in expanding its customer base and gaining greater uptake of its Aprevo technology platform. Additionally, while the company has shown success in lumbar fusion, they may face more difficulties in launching and penetrating the cervical spine market due to a higher success rate of traditional fusion procedures and potential challenges in securing reimbursement and specific codes for custom implants.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.